Oak Associates Ltd. OH Decreases Stake in Elevance Health, Inc. $ELV

Posted by Brian Himes on Jul 24th, 2026

Oak Associates Ltd. OH lessened its holdings in shares of Elevance Health, Inc. (NYSE:ELV – Free Report) by 51.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,054 shares of the company’s stock after selling 2,210 shares during the period. Oak Associates Ltd. OH’s holdings in Elevance Health were worth $601,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Kemnay Advisory Services Inc. purchased a new position in shares of Elevance Health in the 4th quarter valued at about $31,000. J.Safra Asset Management Corp purchased a new stake in Elevance Health during the fourth quarter worth about $32,000. WealthCollab LLC boosted its holdings in Elevance Health by 42.2% during the first quarter. WealthCollab LLC now owns 91 shares of the company’s stock worth $27,000 after buying an additional 27 shares in the last quarter. ORG Partners LLC grew its position in Elevance Health by 120.4% during the fourth quarter. ORG Partners LLC now owns 108 shares of the company’s stock worth $38,000 after buying an additional 59 shares during the period. Finally, Dorato Capital Management purchased a new position in Elevance Health in the fourth quarter valued at about $41,000. Institutional investors and hedge funds own 89.24% of the company’s stock.

Insider Buying and Selling at Elevance Health

In related news, Director Robert L. Dixon, Jr. sold 151 shares of the company’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $401.77, for a total transaction of $60,667.27. Following the transaction, the director owned 10,734 shares of the company’s stock, valued at approximately $4,312,599.18. This represents a 1.39% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.34% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several brokerages have recently commented on ELV. Morgan Stanley boosted their price target on Elevance Health from $352.00 to $404.00 and gave the stock an “equal weight” rating in a research note on Thursday, June 4th. Robert W. Baird boosted their target price on Elevance Health from $331.00 to $393.00 and gave the stock a “neutral” rating in a research report on Thursday, July 16th. Deutsche Bank Aktiengesellschaft raised Elevance Health from a “hold” rating to a “buy” rating and upped their target price for the company from $363.00 to $498.00 in a report on Wednesday, May 20th. Bank of America lifted their price target on Elevance Health from $435.00 to $460.00 and gave the stock a “buy” rating in a research note on Thursday, June 4th. Finally, Weiss Ratings upgraded shares of Elevance Health from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, May 18th. Fifteen analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat, Elevance Health currently has a consensus rating of “Moderate Buy” and an average target price of $440.90.

Read Our Latest Report on ELV

Elevance Health Stock Down 2.7%

Shares of NYSE:ELV opened at $378.48 on Friday. The company has a quick ratio of 1.52, a current ratio of 1.52 and a debt-to-equity ratio of 0.68. The company has a market capitalization of $82.08 billion, a P/E ratio of 16.82, a P/E/G ratio of 2.24 and a beta of 0.67. Elevance Health, Inc. has a 52-week low of $273.71 and a 52-week high of $436.24. The stock’s fifty day simple moving average is $399.00 and its 200-day simple moving average is $356.37.

Elevance Health (NYSE:ELV – Get Free Report) last posted its quarterly earnings data on Wednesday, July 15th. The company reported $7.45 EPS for the quarter, topping analysts’ consensus estimates of $6.21 by $1.24. The firm had revenue of $49.83 billion during the quarter, compared to analysts’ expectations of $48.88 billion. Elevance Health had a return on equity of 14.64% and a net margin of 2.47%.The firm’s quarterly revenue was up .8% compared to the same quarter last year. During the same quarter last year, the business posted $8.84 EPS. As a group, equities research analysts forecast that Elevance Health, Inc. will post 27.08 earnings per share for the current fiscal year.

Elevance Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 25th. Stockholders of record on Thursday, September 10th will be given a $1.72 dividend. This represents a $6.88 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date of this dividend is Thursday, September 10th. Elevance Health’s payout ratio is currently 30.58%.

Elevance Health Profile

(Free Report)

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.